A Highly Potent Bi-thiazole Inhibitor of LOX Rewires Collagen Architecture and Enhances Chemoresponse in Triple-Negative Breast Cancer

Investigators discovered bi-thiazole derivatives as potent lysyl oxidase (LOX) inhibitors by robust screening of drug-like molecules combined with cell/recombinant protein-based assays. LXG6403 showed favorable pharmacokinetic properties, globally changed ECM/collagen architecture, and reduced tumor stiffness.